Compare Ascendis Pharma A/S (ASND) vs Allbirds Inc (BIRD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Allbirds Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Allbirds Inc trades at $3.14 (market cap $27.52M). The key difference: Ascendis Pharma A/S is far larger — about 644.6× Allbirds Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Allbirds Inc nearer its low. Which is the better fit depends on your goals.
| ASND | BIRD | |
|---|---|---|
Market Cap | $17.74B | $27.52M |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $16.99 |
52-Week Low | $163.32 | $2.39 |
Enterprise Value | $18.11B | $46.39M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
BIRD (Smartbird) trades at $3.13, down 9.54% today, reflecting volatility following its pivot from footwear to AI infrastructure. The stock shows a bearish technical signal with mixed oscillators, while fundamentals reveal persistent losses: revenue declined to $152.47M in 2025 with a net margin of -53.36%. Recent news highlights the company's rebranding and new CEO appointment, driving significant stock movements amid investor speculation on its AI strategy.
The outlook is highly speculative, with opportunity stemming from potential AI business execution, but substantial risks remain due to negative profitability, cash burn, and reliance on a unproven new direction. Analyst consensus is cautious, with 78.57% hold ratings, indicating skepticism about near-term turnaround prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Allbirds Inc
Allbirds Inc is a global lifestyle brand that innovates with naturally derived materials to make footwear and apparel products. Its primary source of revenue is from sales of shoes and apparel products in its directly owned digital and physical retail channels.
Read more on BIRD →
